护肝颗粒冲剂对中重度乙肝患者肝纤维化生化指标的影响

The effect of Hugankeli granula on the biochemical parameters related to hepatic fibrosis in patients with moderate and severe chronic hepatitis B

目的观察护肝颗粒冲剂对中重度慢性乙型肝炎患者肝纤维化指标的影响。方法82例中重度慢性乙型肝炎患者随机分为2组:治疗组(41例)给予护肝颗粒冲剂10g,每日3次,联合常规护肝降酶药物治疗;对照组(41例)采用常规护肝降酶药物治疗。疗程均为3个月。治疗前、后分别检测2组血清透明质酸(HA)、IV型胶原(CIV)、III型前胶原(PCIII)、层粘连蛋白(LN)水平。结果治疗组治疗后血清HA、CIV、PCIII、LN明显下降(P<0.01),对照组各指标无明显变化(P>0.05),2组治疗后比较,差异有统计学意义(P<0.01)。结论护肝颗粒冲剂有较好的抗肝纤维化作用。

Objective To observe the effect of Hugankeli granula on the biochemical parameters related to hepatic fibrosis in patients with hepatitis B. Methods 82 patients with moderate and severe chronic hepatitis B were randomly divided into two groups. 41 patients in control group were treated by the routine drugs of protecting liver and decreasing the enzymes, while the other 41 patients in treatment group, on the therapeutic basis of control group, were treated by Hugankeli granula 10g once,3 times a day, with a treatment course of 3 months for both groups. The serum levels of hyaluronic acid （ HA ）, type Ⅳ collagen （ CⅣ ）, precollagen type Ⅲ（ PC Ⅲ） and laminin （LN） were detected before and after treatment in both groups. Results The serum levels of HA, CIV, PC Ⅲ and LN in treatment group were significandy decreased after treatment（ P 〈 0.01 ）, however, there were no significant changes in these parameters in control group after treatment（ P 〉 0.05） .There were significant differences in these parameters after treatment between the two groups（ P 〈 0.01）. Conclusion Hugankeli granula is an effective drug to resist the hepatic fibrosis